Cohen I, Altaras M M, Shapira J, Tepper R, Rosen D J, Cordoba M, Zalel Y, Figer A, Yigael D, Beyth Y
Department of Obstetrics and Gynecology, Sapir Medical Center, Kfar Saba, Israel.
Int J Gynecol Pathol. 1996 Apr;15(2):152-7. doi: 10.1097/00004347-199604000-00010.
Various endometrial lesions were more frequent among asymptomatic postmenopausal breast cancer patients who were treated with tamoxifen for > 48 consecutive months (30.8%) when compared with similar patients who were treated for 6-24 months or for 25-48 months (20.8% and 12.5%, respectively). However, this difference was not statistically significant. There were also no significant differences in the frequency of the various endometrial lesions between these three groups, although endometrial polyps were more frequently found among those treated for > 48 months. Overall, 20.7% of the 164 tamoxifen-treated patients in the study had an endometrial pathology. It can be concluded that there is a slight tendency among those postmenopausal patients who have been treated for > 48 consecutive months to have a higher frequency of endometrial lesions.
与接受他莫昔芬治疗6 - 24个月或25 - 48个月的类似患者相比,连续接受他莫昔芬治疗超过48个月的无症状绝经后乳腺癌患者中,各种子宫内膜病变更为常见(30.8%),后两组患者的相应比例分别为20.8%和12.5%。然而,这种差异无统计学意义。这三组患者中各种子宫内膜病变的发生率也无显著差异,不过在接受治疗超过48个月的患者中,子宫内膜息肉更为常见。总体而言,该研究中164例接受他莫昔芬治疗的患者中有20.7%存在子宫内膜病变。可以得出结论,连续接受治疗超过48个月的绝经后患者有子宫内膜病变发生率较高的轻微趋势。